

Review article

The Beneficial Biological Properties of Salicylic Acid

Pavle Randjelović¹, Slavimir Veljković¹, Nenad Stojiljković¹, Dušan Sokolović²,
Ivan Ilić³, Darko Laketić⁴, Dušica Randjelović⁵, Nebojša Randjelović⁶

¹University of Niš, Faculty of Medicine, Department of Physiology, Niš, Serbia

²University of Niš, Faculty of Medicine, Department of Biochemistry, Niš, Serbia

³University of Niš, Faculty of Medicine, Institute of Pathology, Niš, Serbia

⁴Urology Clinic, Clinical Hospital Center „Dr Dragiša Mišović“ –Dedinje, Belgrade, Serbia

⁵Pediatric Clinic, Clinical Center Niš, Serbia

⁶University of Niš, Faculty of Sport and Physical Education, Niš, Serbia

SUMMARY

Salicylic acid is a phytochemical with beneficial effects on human well-being. Salicylic acid is a phenolic compound and is present in various plants where it has a vital role in protection against pathogenic agents. Natural sources include fruits, vegetables and spices. The most famous and defined effect of salicylic acid is prostaglandin synthesis inhibition. Salicylic acid has anti-inflammatory effects through suppression of transcription of genes for cyclooxygenase. Most of the pharmacological properties of salicylic acid can be contributed to the inhibition of prostaglandin synthesis. Also, it was discovered that salicylic acid has other *in vivo* cyclooxygenase-independent pathways. Since salicylic acid does not inhibit cyclooxygenase considerably, the anti-inflammatory effect is not a consequence of direct inhibition of cyclooxygenase activity. Because of its fundamental role, it was suggested that inhibition of nuclear factor kappa B by salicylic acid is one of the key anti-inflammatory mechanisms of action for salicylates. One of the most studied properties of salicylic acid is its antioxidative activity. Salicylic acid is a confirmed inhibitor of oxidative stress. Salicylic acid is capable of binding iron. This fact is significant for antioxidative effect of salicylic acid because iron has an important function in the course of lipid peroxidation.

Key words: salicylic acid, biological activity, phytochemicals, salicylates

Corresponding author:

Pavle Randjelović

e-mail: pavleus@gmail.com

INTRODUCTION

Salicylic acid (SA) belongs to the group of the phytochemicals with beneficial effects on human health. Salicylic acid is a phenolic compound and can be found in plants where it has a crucial role in the defense against pathogenic agents (1, 2). It is present in various amounts in fruits, vegetables and spices. It is more popular as the main metabolite and active component of acetyl salicylic acid (ASA), an anti-inflammatory drug used in clinical practice for more than 100 years (3). In the last decade it has been accepted that chronic intake of ASA in low doses can be effective in the prevention of cardiovascular disease (CVD) and colorectal carcinoma (4, 5). This fact supports the hypothesis that beneficial health effects of fruits and vegetables partially depends on the presence of SA in it. Salicylic acid can be detected in the blood of normal, healthy population without record of ASA usage, suggesting the origin from plant-based food (6).

The analgesic effect of willow bark has been known since Hippocrates first described it. It was used through history in traditional medicine for treating pain. In the year 1859, an active component, SA, was isolated and synthesized. SA is crystal organic carboxylic acid. It is soluble in alcohol, while poorly soluble in water. Since it has a damaging effect on gastric mucosa, in 1897 Felix Hoffman synthesized buffered form ASA (7).

INHIBITION OF PROSTAGLANDIN SYNTHESIS

The most investigated and described effect of SA is the inhibition of the synthesis of prostaglandins (PGs)(8). PGs are members of the lipid family and are produced from polyunsaturated fatty acids by enzyme cyclooxygenase (COX). Almost all the cells in the human body can make PGs from arachidonic acid which is present in the cell membrane phospholipids. After being synthesized, PGs act as autocrine or paracrine lipid mediators in maintaining local homeostasis in the organism. Prostaglandins have numerous physiological functions like: a) protection of the gastrointestinal tract; b) regulation of the kidney homeostasis; c) regulation of sleep and wakening and d) regulation of body temperature (9). The synthesis of PGs is generally very small in tissues without inflammation. On the other hand, during the

process of inflammation there is a marked change in the concentration and type of PGs.

First, it was considered that SA inhibits the synthesis of PG through COX inhibition (10). However, in 1999, a new pathway of PG inhibition was proposed for SA and ASA. Xu et al. (11) showed that SA and ASA act anti-inflammatory by suppressing transcription of genes for COX. Most of the pharmacological effects of SA can be explained by PG synthesis inhibition. Also, it was described that SA has other COX-independent mechanisms of action (12).

ANTI-INFLAMMATORY EFFECTS

It is considered that SA and ASA have equal anti-inflammatory properties (13). Since SA does not inhibit COX considerably, the anti-inflammatory effect is not mediated through direct inhibition of COX activity. Moreover, ASA has a short half-life in the blood. ASA is deacetylated to form SA, which is responsible for in vivo effects. It was shown that anti-inflammatory action of SA is mediated by the inhibition of leukocyte function and inhibition of the expression of different proinflammatory genes (14).

Inducible nitric oxide synthase (iNOS) has an important role in the process of inflammation and tissue injury. Similarly to COX-2, the expression of iNOS is induced by cytokines and lipopolysaccharide (LPS). This enzyme catalyzes the production of nitric oxide (NO) which acts further by activation of guanylate cyclase as well as by nitration and nitrosylation of proteins. Furthermore, NO reacts with superoxide anion and creates peroxynitrite. Peroxynitrite is highly reactive and is capable of damaging cells. It was shown that SA inhibits expression of iNOS stimulated by LPS and interferon gamma (IFN γ) in alveolar macrophages of rats (15, 16). Ruy et al. (17) described the suppression of iNOS by SA in RAW 264.7 cells at post-translational or translational level but not at the level of transcription. Sakitani et al. (18) also demonstrated the inhibition of iNOS expression by SA in hepatocytes at the level of translation but not transcription.

Even though the most studies showed that SA inhibits the expression of iNOS in pharmacological doses, there were some reports with similar results only with supratherapeutic doses (19). Paradoxically, Nishio et al. (20) showed the opposite effect of SA to iNOS expression. They found that sodium salicylate increases the synthesis of iNOS and NO in vascular smooth muscle cells, although the observed effect was

weak. These contradictory findings suggest that the effect of SA on iNOS expression depends on cell type, experimental conditions and stimulation.

Sodium salicylate has proved itself as successful in suppression of acute inflammatory reactions in animals (21). Abramson et al. (13) showed that ASA inhibits neutrophil function. It was suggested that it was a consequence of adenosine synthesis induction (22). The results from recent study have indicated that SA can reduce oxidative-stress associated renal injury by reducing oxygen free radicals and lipid peroxidation in gentamicin-treated rats (23).

NUCLEAR FACTOR KAPPA B INHIBITION

It is known that high concentration of SA can react with kinases, including mitogen activated protein kinase (MAPK). Most authors point out that the reaction of SA with kinases is inhibitory. It can be one of the reasons for inhibitory effects of SA on several nuclear transcription factors. Among transcription factors, the research focus is on the interaction between SA and nuclear factor kappa b (NF- κ B). The mentioned nuclear factor is a key element in cellular response to inflammatory stimulus. The inhibition of NF- κ B by SA was first reported by Kopp and Ghosh in 1994 (24) and in many experiments later on (25, 26). Since NF- κ B regulates the expression of pro-inflammatory enzymes, cytokines, chemokines, receptors and cell adhesion molecules, it is usually named as central mediator of immune response (27). Because of its central role, it was proposed that inhibition of NF- κ B by SA is one of the main anti-inflammatory mechanisms of action for salicylates (24).

Nuclear factor kappa B is involved in the control of transcription of many genes not involved in immune response. That is why NF- κ B is more a regulator of response to stress than central mediator of immune response. Nuclear factor kappa B also functions as apoptosis regulator, either as inductor or, more often, as the inhibitor of programmed cell death. The final effect of NF- κ B on apoptosis depends on cell type and inductor type. Nuclear factor kappa B transcription factors are regulated primarily by interaction with inhibitory I κ B proteins. In most cells, NF- κ B is in cytoplasm in inactive form bound to I κ B. Most NF- κ B activators proteolyse I κ B. The released

NF- κ B is then transferred to the nucleus where it binds to κ B region in promoter of target genes and regulates transcription. Stimulation of cells by LPS in the presence of SA resulted in the lack of LPS-induced proteolysis of I κ B, which proved that the observed inhibition of NF- κ B is mediated by inhibition of phosphorylation and/or proteolysis of I κ B (24). The serum concentrations of SA between 1 and 2 mM are necessary for anti-inflammatory effects, while concentrations higher than 6 mM are toxic (28).

ANTIOXIDATIVE PROPERTIES

One of the most studied characteristic of SA is its antioxidative property. Since SA is used as a chemical trap for hydroxyl radical, it was reported that SA could reduce tissue damage caused by hypoxia/reoxygenation (29). However, it is not quite clear if antioxidative property of SA has the influence on its anti-inflammatory effects.

For example, the effect of SA on neutrophils adhesion can be explained by the inhibition of extracellular MAPK activation necessary for integrin activity (30). Also, it was shown that SA inhibits the activation of transcription factors like NF- κ B (24). One of the studies has described a new pharmacological effect of SA as the inhibition of transcription for several cytokines genes (31). Therefore, it is possible that there are additional, undiscovered mechanisms of action of SA.

Salicylic acid is a verified inhibitor of oxidative stress. Sagone et al. (32) showed that SA reacted with hydroxyl radicals in granulocytes and created metabolites. Also, SA decreased superoxide anion radicals by acting on NADPH activity which decreased reactive oxygen species (ROS) in human endothelial cells in vitro (33). Salicylic acid can bind iron (Fe^{2+}) (34). This fact is important because Fe^{2+} has an important function in the process of lipid peroxidation. The iron creates not only OH \cdot through Fenton reaction but is involved in the creation of peroxy and alkoxy radicals (35).

CONCLUSION

There is no doubt that SA is an important natural compound widely available in nature with proven and described beneficial biological properties. According to some authors, salicylic acid deserves an

epithet of a vitamin, "Vitamin S". Most of the literature-based data about SA is from studies dealing with disease preventive properties of ASA. Even though SA is the main in vivo metabolite of ASA, we cannot equalize the effect of those two related molecules inside the human body. On the other hand, natural sources of SA like plants are also loaded with other health-promoting phytochemical which can be present in higher quantities. Some of them share described biological effects of SA. In this context, we should not draw straightforward conclusions about SA and human health. Finally, we can conclude that SA is a potent and important naturally occurring

phytochemical with numerous health-promoting effects, but further experimental studies using isolated SA are needed to fully understand its biological effects.

Acknowledgements

This work was supported by the Ministry of Science and Technological Development, Republic of Serbia (grants 43012 and 172061).

References

1. Dempsey DA, Klessing DF. Salicylic acid, active oxygen species and system acquired resistance in plants. *Trends Cell Biol* 1994; 4:334-8.
[http://dx.doi.org/10.1016/0962-8924\(94\)90235-6](http://dx.doi.org/10.1016/0962-8924(94)90235-6)
2. Dangl J. Innate immunity. Plant just say NO to pathogens. *Nature* 1998; 394:525-7.
<http://dx.doi.org/10.1038/28958>
3. Stanley P, Hegedus R. Aspirin – the first hundred years. *Biologist* 2000; 47: 269-71.
4. Sanmuganathan PS, Ghahramani P, Jackson P et al. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. *Heart* 2001; 85: 265-71.
<http://dx.doi.org/10.1136/heart.85.3.265>
5. Gasche C. Review Article: The chemoprevention of colorectal carcinoma. *Aliment Pharmacol Ther* 2004; 20: 31-35.
<http://dx.doi.org/10.1111/j.1365-2036.2004.02045.x>
6. Duthie GG, Wood AD. Natural salicylates: foods, functions and disease prevention. *Food Funct* 2011; 2:515-520.
<http://dx.doi.org/10.1039/c1fo10128e>
7. Schindler PE Jr, Fields WS. Aspirin Therapy. Walker and Company, New York, 1978.
8. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. *Nat New Biol* 1971; 231:232-235.
<http://dx.doi.org/10.1038/newbio231232a0>
9. Murray RK, Granner DK, Mayes PA, Rodwell VW. Harper's Biochemistry. 21st edn. Appleton & Lange, Norwalk, 1988.
10. Ohki S, Ogino N, Yamamoto S, Hayaishi O. Prostaglandin hydroperoxidase, an integral part of prostaglandin endoperoxidase synthetase from bovine vesicular gland microsomes. *J Biol Chem* 1979; 254:829-36.
11. Xu XM, Sansores-Garcia L, Chen XM, Matijevic-Aleksic N, Du M, Wu KK. Suppression of inducible cyclooxygenase-2 gene transcription by aspirin and sodium salicylate. *Proc Natl Acad Sci USA* 1999; 96:5292-5297.
<http://dx.doi.org/10.1073/pnas.96.9.5292>
12. Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. *FASEB J* 2001; 15:2057-2072.
<http://dx.doi.org/10.1096/fj.01-0390rev>
13. Abramson SB, Leszczynska-Piziak J, Clancy RM, Philips M, Weissmann G. Inhibition of neutrophil function by aspirin-like drugs (NSAIDs): requirement for assembly of heterotrimeric G proteins in bilayer phospholipid. *Biochem Pharmacol* 1994; 47:563-572.
[http://dx.doi.org/10.1016/0006-2952\(94\)90189-9](http://dx.doi.org/10.1016/0006-2952(94)90189-9)
14. Abramson SB, Weissmann G. The mechanisms of action of nonsteroidal antiinflammatory drugs. *Arthritis Rheum* 1989; 32:1.

- <http://dx.doi.org/10.1002/anr.1780320102>
15. Aeberhard EE, Henderson SA, Arabolos NS et al. Nonsteroidal anti-inflammatory drugs inhibit expression of the inducible nitric oxide synthase gene. *Biochem Biophys Res Commun* 1995; 208:1053-1059.
<http://dx.doi.org/10.1006/bbrc.1995.1441>
 16. Kepka-Lenhart D, Chen LC, Morris SM. Novel actions of aspirin and sodium salicylate: discordant effects on nitric oxide synthesis and induction of nitric oxide synthase mRNA in a murine macrophage cell line. *J Leukoc Biol* 1996; 59:840-6.
 17. Ryu YS, Lee JH, Seok JH et al. Acetaminophen inhibits iNOS gene expression in RAW 264.7 macrophages: differential regulation of NF-kappaB by acetaminophen and salicylates. *Biochem Biophys Res Commun* 2000; 272:758-64.
<http://dx.doi.org/10.1006/bbrc.2000.2863>
 18. Sakitani K, Kitade H, Inoue K et al. The anti-inflammatory drug sodium salicylate inhibits nitric oxide formation induced by interleukin-1beta at a translational step, but not at a transcriptional step, in hepatocytes. *Hepatology* 1997; 25:416-420.
<http://dx.doi.org/10.1002/hep.510250226>
 19. Chung CK, Koo HN, Chung KY et al. Inhibitory effect of sodium salicylate on nitric oxide production from TM4 sertoli cells. *Int J Immunopharmacol* 2000; 22:685-692.
[http://dx.doi.org/10.1016/S0192-0561\(00\)00031-X](http://dx.doi.org/10.1016/S0192-0561(00)00031-X)
 20. Nishio E, Watanabe Y. Aspirin and salicylate enhances the induction of inducible nitric oxide synthase in cultured rat smooth muscle cells. *Life Sci* 1998; 63:429-439.
[http://dx.doi.org/10.1016/S0024-3205\(98\)00292-6](http://dx.doi.org/10.1016/S0024-3205(98)00292-6)
 21. Cronstein BN, Montesinos MC, Weissmann G. Salicylates and sulfasalazine, but not glucocorticoids, inhibit leukocyte accumulation by an adenosine-dependent mechanism that is independent of inhibition of prostaglandin synthesis and p105 of NFkB. *Proc Natl Acad Sci USA* 1999; 96:6377-6381.
<http://dx.doi.org/10.1073/pnas.96.11.6377>
 22. Catania A, Arnold J, Macaluso A, Hiltz ME, Lipton JM. *Proc Natl Acad Sci USA* 1991; 88:8544-8547.
<http://dx.doi.org/10.1073/pnas.88.19.8544>
 23. Randjelovic P, Veljkovic S, Stojiljkovic N et al. Salicylic acid attenuates gentamicin-induced nephrotoxicity in rats. *Scientific World Journal* 2012; 2012:390613.
<http://dx.doi.org/10.1100/2012/390613>
 24. Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. *Science* 1994; 265:956-9.
<http://dx.doi.org/10.1126/science.8052854>
 25. Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. *Nature* 1998; 396:77-80.
<http://dx.doi.org/10.1038/23948>
 26. Bayon Y, Alonso A, Sanchez Crespo M. 4-Trifluoromethyl derivatives of salicylate, triflusal and its main metabolite 2-hydroxy-4-trifluoromethylbenzoic acid, are potent inhibitors of nuclear factor kappaB activation. *Br J Pharmacol* 1999; 126:1359-66.
<http://dx.doi.org/10.1038/sj.bjp.0702441>
 27. Pahl HL. Activators and target genes of Rel/NFkappaB transcription factors. *Oncogene* 1999; 18:6853-66.
<http://dx.doi.org/10.1038/sj.onc.1203239>
 28. Cianferoni A, Schroeder JT, Kim J et al. Selective inhibition of interleukin-4 gene expression in human T cells by aspirin. *Blood* 2001; 97:1742-1749.
<http://dx.doi.org/10.1182/blood.V97.6.1742>
 29. Colantoni A, de Maria N, Caraceni P, Bernardi M, Floyd RA, Van Thiel DH. Prevention of reoxygenation injury by sodium salicylate in isolated-perfused rat liver. *Free Radic Biol Med* 1998; 25:87-94.
[http://dx.doi.org/10.1016/S0891-5849\(98\)00033-1](http://dx.doi.org/10.1016/S0891-5849(98)00033-1)
 30. Pillinger MH, Capodici C, Rosenthal P et al. Modes of action of aspirin-like drugs: salicylates inhibit erk activation and integrin-dependent neutrophil adhesion. *Proc Natl Acad Sci U.S.A* 1998; 95:14540-14545.

<http://dx.doi.org/10.1073/pnas.95.24.14540>

31. Aceves M, Duenas A, Gomez C, San Vicente E, Crespo MS, Garcia-Rodriguez C. A new pharmacological effect of salicylates: inhibition of NFAT-dependent transcription. *J Immunol* 2004; 173:5721-5729.
<http://dx.doi.org/10.4049/jimmunol.173.9.5721>
32. Sagone AL Jr, Husney RM. Oxidation of salicylates by stimulated granulocytes: evidence that these drugs act as free radical scavengers in biological systems. *J Immunol* 1987; 138:2177-83.
33. Dragomir E, Manduteanu I, Voinea M, et al. Aspirin rectifies calcium homeostasis, decreases reactive oxygen species, and increases NO production in high glucose-exposed human endothelial cells. *J Diabetes Complications* 2004; 18:289-99.
<http://dx.doi.org/10.1016/j.jdiacomp.2004.03.003>
34. Kotrly S, Sucha L. *Handbook of Chemical Equilibria in Analytical Chemistry*. Ellis Horwood Limited, Chichester, 1985.
35. Halliwell B, Gutteridge JMC. Role of free radicals and catalytic metal ions in human disease: an overview. In: Packer L, Glazer AN (eds), *Methods Enzymol*, vol. 186. Academic Press, California, 1990: 1-5.
[http://dx.doi.org/10.1016/0076-6879\(90\)86093-b](http://dx.doi.org/10.1016/0076-6879(90)86093-b)

Povoljna biološka svojstva salicilne kiseline

Pavle Randelović¹, Slavimir Veljković¹, Nenad Stojiljković¹, Dušan Sokolović²,
Ivan Ilić³, Darko Laketić⁴, Dušica Randelović⁵, Nebojša Randelović⁶

¹Univerzitet u Nišu, Medicinski fakultet, Institut za fiziologiju, Niš, Srbija

²Univerzitet u Nišu, Medicinski fakultet, Institut za biohemiju, Niš, Srbija

³Univerzitet u Nišu, Medicinski fakultet, Institut za patologiju, Niš, Srbija

⁴Klinika za urologiju, Koliničko-bolnički centar "Dr Dragiša Mišović – Dedinje", Beograd, Srbija

⁵Klinika za dečije interne bolesti, Klinički centar Niš, Niš, Niš, Srbija

⁶Univerzitet u Nišu, Fakultet sporta i fizičkog vaspitanja, Niš, Srbija

SAŽETAK

Salicilna kiselina je fitohemikalija sa povoljnim efektima na ljudsko zdravlje. Salicilna kiselina je fenolna komponenta i prisutna je u različitim biljkama, gde ima važnu ulogu u zaštiti od patogenih agenasa. U prirodi se nalazi u voću, povrću i začинима. Najpoznatiji i najbolje proučen efekat salicilne kiseline je inhibicija sinteze prostanglandina. Salicilna kiselina ostvaruje anti-zapaljensko dejstvo preko supresije gena za ciklooksigenazu. Većina farmakoloških svojstava salicilne kiseline mogu se objasniti inhibicijom sinteze prostanglandina. Otkriveno je da salicilna kiselina pored ovog ima i druga *in vivo* dejstva. Pošto salicilna kiselina ne inhibira značajno ciklooksigenazu, anti-zapaljensko dejstvo nije posledica direktne inhibicije ovog enzima. Predloženo je da je inhibicija nuklearnog faktora kapa B od strane salicilata jedno od glavnih mehanizama anti-zapaljenskog dejstva salicilata. Jedno od najviše proučavanih svojstava salicilne kiseline je antioksidativna aktivnost. Salicilna kiselina je dokazani inhibitor oksidativnog stresa. Salicilna kiselina ima sposobnost vezivanja gvožđa. Ova činjenica je značajna za antioksidativno dejstvo salicilne kiseline zbog toga što gvožđe ima važnu ulogu u procesu lipidne peroksidacije.

Ključne reči: salicilna kiselina, biološka aktivnost, fitohemikalije, salicilati